Our goal is to have a clinical trial option available for patients at every stage of disease. We offer a range of clinical trials for newly-diagnosed CLL, relapsed/refractory CLL, as well as Richter's syndrome, a condition where CLL turns into an aggressive form of lymphoma.
Featured Clinical Trials
Newly-Diagnosed CLL
22-597: Randomized, phase 3 study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study
Principal Investigator: Inhye Ahn, MD
17-105: A pilot study of a personalized neoantigen cancer vaccine with and without low-dose cyclophosphamide or pembrolizumab in treatment naïve, asymptomatic patients with IGHV unmutated chronic lymphocytic leukemia
Principal Investigator: Inhye Ahn, MD
Relapsed/Refractory CLL
24-449: A Phase 1/2, open label, study of roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor in patients with refractory/relapsed Chronic Lymphocytic Leukemia (CLL) in combination with venetoclax and rituximab
Principal Investigator: Jennifer Brown, MD, PhD
21-712: A multicenter, open-label, phase 2 study to evaluate the efficacy and safety of venetoclax-obinutuzumab retreatment in patients with recurring chronic lymphocytic leukemia
Principal Investigator: Matthew Davids, MD, MMSc
21-279: A phase 2 trial of zanubrutinib and venetoclax in previously treated CLL/SLL patients
Principal Investigator: Inhye Ahn, MD
Clearance of Minimal Residual Disease in CLL
24-582: Phase 2, open-label, prospective single-arm, multi-center clinical trial to evaluate if adding venetoclax to patients on covalent BTKI FOR 1L CLL can achieve deep durable remissions (by uMRD 10-4) to allow off treatment period
Principal Investigator: Matthew Davids, MD, MMSc
Richter’s Syndrome
23-429: A phase 2 study of glofitamab as monotherapy or in combination with polatuzumab vedotin or atezolizumab in Richter's transformation
Principal Investigator: Matthew Davids, MD, MMSc
Learn more about clinical trials for CLL patients.
Translational Science
Translational science, which quickly moves laboratory findings into clinical practice, is also a key focus of the Center for Chronic Lymphocytic Leukemia. This includes:
- Examining genetic material of a variety of CLLs in order to identify genetic changes that cause CLL
- Studying functional response of CLL cells to novel agent therapies to predict response to therapy and identify novel resistance mechanisms
- Providing CLL samples to a large network of collaborators who are working to better understand how CLL develops and how we can best target it with the goal of finding a cure